abstract |
The present invention relates to antibody-drug (ADC) conjugates containing duocarmycin for use in the treatment of solid human tumors and hematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, cancer of ovary, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma and acute lirifoblastic leukemia; in particular, the present invention relates to ADC containing duocarmycin for use in the treatment of solid human tumors with HER2 IHC 2+ or 1+ tissue status and negative for HER2 FISH; Advantageously, the present invention relates to ADCs containing duocarmycin for use in the treatment of triple-negative breast cancer (TNBC). |